$1.11 Billion is the total value of FRAZIER MANAGEMENT LLC's 31 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 19.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARQT | ARCUTIS BIOTHERAPEUTICS INC | $308,904,000 | -3.1% | 10,542,790 | 0.0% | 27.73% | -0.9% | |
| PHAT | PHATHOM PHARMACEUTICALS INC | $213,691,000 | +11.4% | 5,827,415 | 0.0% | 19.18% | +13.9% | |
| PCVX | VAXCYTE INC | $114,046,000 | +56.2% | 2,309,554 | 0.0% | 10.24% | +59.7% | |
| MIRM | MIRUM PHARMACEUTICALS INC | $68,734,000 | -1.0% | 3,566,912 | 0.0% | 6.17% | +1.2% | |
| PASG | PASSAGE BIO INC | $65,671,000 | -52.0% | 5,009,219 | 0.0% | 5.90% | -51.0% | |
| IOVA | IOVANCE BIOTHERAPEUTICS INC | $43,224,000 | +19.9% | 1,312,999 | 0.0% | 3.88% | +22.6% | |
| Buy | TRILLIUM THERAPEUTICS INC | $39,555,000 | +77.5% | 2,788,443 | +1.2% | 3.55% | +81.5% | |
| KRYS | KRYSTAL BIOTECH INC | $38,530,000 | +3.9% | 895,000 | 0.0% | 3.46% | +6.3% | |
| ANAB | ANAPTYSBIO INC | $34,168,000 | -34.0% | 2,316,447 | 0.0% | 3.07% | -32.5% | |
| TBIO | TRANSLATE BIO INC | $29,708,000 | -24.1% | 2,182,789 | 0.0% | 2.67% | -22.4% | |
| ALPN | ALPINE IMMUNE SCIENCES INC | $22,603,000 | -9.5% | 2,571,450 | 0.0% | 2.03% | -7.5% | |
| COLL | COLLEGIUM PHARMACEUTICAL INC | $19,647,000 | +19.0% | 943,666 | 0.0% | 1.76% | +21.7% | |
| SNDX | SYNDAX PHARMACEUTICALS INC | $19,484,000 | -0.4% | 1,320,045 | 0.0% | 1.75% | +1.8% | |
| ADVM | ADVERUM BIOTECHNOLOGIES INC | $14,801,000 | -50.7% | 1,437,028 | 0.0% | 1.33% | -49.6% | |
| ISEE | IVERIC BIO INC | $13,336,000 | +10.6% | 2,364,500 | 0.0% | 1.20% | +13.0% | |
| RCKT | ROCKET PHARMACEUTICALS INC | $12,070,000 | +9.2% | 528,000 | 0.0% | 1.08% | +11.8% | |
| APTX | APTINYX INC | $10,782,000 | -19.0% | 3,190,079 | 0.0% | 0.97% | -17.1% | |
| FRLN | New | FREELINE THERAPEUTICS HLDGSsponsored ads | $8,586,000 | – | 550,000 | +100.0% | 0.77% | – |
| GRTS | GRITSTONE ONCOLOGY INC | $5,464,000 | -60.1% | 2,061,758 | 0.0% | 0.49% | -59.2% | |
| ALNA | ALLENA PHARMACEUTICALS INC | $4,929,000 | -6.3% | 3,330,373 | 0.0% | 0.44% | -4.1% | |
| RGNX | New | REGENXBIO INC | $4,794,000 | – | 174,200 | +100.0% | 0.43% | – |
| CDTX | CIDARA THERAPEUTICS INC | $3,740,000 | -22.8% | 1,312,258 | 0.0% | 0.34% | -20.9% | |
| CRDF | New | CARDIFF ONCOLOGY INC | $3,689,000 | – | 260,000 | +100.0% | 0.33% | – |
| BLU | New | BELLUS HEALTH INC NEW | $2,959,000 | – | 1,296,743 | +100.0% | 0.27% | – |
| NABRIVA THERAPEUTICS PLC | $2,269,000 | -21.0% | 4,256,526 | 0.0% | 0.20% | -19.0% | ||
| SRRA | SIERRA ONCOLOGY INC | $2,164,000 | -11.8% | 202,803 | 0.0% | 0.19% | -9.8% | |
| VTVT | VTV THERAPEUTICS INCcl a | $1,880,000 | -21.3% | 1,062,000 | 0.0% | 0.17% | -19.5% | |
| NERV | New | MINERVA NEUROSCIENCES INC | $1,749,000 | – | 550,000 | +100.0% | 0.16% | – |
| ITRM | ITERUM THERAPEUTICS PLC | $1,615,000 | -11.8% | 1,538,316 | 0.0% | 0.14% | -9.9% | |
| BELLICUM PHARMACEUTICALS INC | $691,000 | -11.5% | 105,144 | 0.0% | 0.06% | -10.1% | ||
| ETTX | Sell | ENTASIS THERAPEUTICS HLDGS I | $408,000 | -60.6% | 199,953 | -42.9% | 0.04% | -59.3% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-11-12
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL INC | 21 | Q4 2020 | 37.0% |
| ANAPTYSBIO INC | 20 | Q4 2021 | 63.7% |
| CIDARA THERAPEUTICS INC | 20 | Q3 2020 | 17.2% |
| IOVANCE BIOTHERAPEUTICS INC | 19 | Q4 2021 | 13.7% |
| ALLENA PHARMACEUTICALS INC | 18 | Q1 2022 | 11.9% |
| ALPINE IMMUNE SCIENCES INC | 18 | Q4 2021 | 9.1% |
| APTINYX INC | 15 | Q4 2021 | 16.9% |
| KRYSTAL BIOTECH INC | 14 | Q4 2021 | 9.7% |
| GRITSTONE ONCOLOGY INC | 14 | Q4 2021 | 8.2% |
| SIERRA ONCOLOGY INC | 12 | Q4 2019 | 6.6% |
View FRAZIER MANAGEMENT LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-10 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-08 |
| 13F-HR | 2021-11-12 |
| 13F-HR | 2021-08-11 |
| 13F-HR | 2021-05-12 |
| 13F-HR | 2021-02-11 |
| 13F-HR | 2020-11-12 |
| 13F-HR | 2020-08-04 |
View FRAZIER MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.